Allegro Ophthalmics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Allegro Ophthalmics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Allegro Ophthalmics: 4 sponsored US clinical trials, none currently recruiting.
Allegro Ophthalmics sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Symptomatic Focal Vitreomacular Adhesion, with 1 trials.
Upper-quartile sponsor footprint
Allegro Ophthalmics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
NCT03626636
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
NCT02435862
Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema
NCT02348918
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
NCT02153476
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Therapeutic Areas
How the Allegro Ophthalmics early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Symptomatic Focal Vitreomacular Adhesion (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Allegro Ophthalmics: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Allegro Ophthalmics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Allegro Ophthalmics page
4 registered trials is a research-attention snapshot, not an endorsement of Allegro Ophthalmics or any single study.
- None of Allegro Ophthalmics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Symptomatic Focal Vitreomacular Adhesion is the condition Allegro Ophthalmics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Symptomatic Focal Vitreomacular Adhesion trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Allegro Ophthalmics pipeline card: 4 registered trials from official public datasets.Report a data error.